Personal Tumor Antigens in Blood Malignancies: Genomics-directed Identification and Targeting

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2020 Jan 28

PMID 31985488

Citations 9

Authors

Livius Penter

Catherine J Wu

Affiliations

Soon will be listed here.

Abstract

Hematological malignancies have long been at the forefront of the development of novel immune-based treatment strategies. The earliest successful efforts originated from the extensive body of work in the field of allogeneic hematopoietic stem cell transplantation. These efforts laid the foundation for the recent exciting era of cancer immunotherapy, which includes immune checkpoint blockade, personal neoantigen vaccines, and adoptive T cell transfer. At the heart of the specificity of these novel strategies is the recognition of target antigens presented by malignant cells to T cells. Here, we review the advances in systematic identification of minor histocompatibility antigens and neoantigens arising from personal somatic alterations or recurrent driver mutations. These exciting efforts pave the path for the implementation of personalized combinatorial cancer therapy.

Citing Articles

Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA Mutations.

Penter L, Cieri N, Maurer K, Kwok M, Lyu H, Lu W Blood Cancer Discov. 2024; 5(6):442-459.

PMID: 39236287 PMC: 11528187. DOI: 10.1158/2643-3230.BCD-23-0138.

Single-cell genomics-based immune and disease monitoring in blood malignancies.

Rathgeber A, Ludwig L, Penter L Clin Hematol Int. 2024; 6(2):62-84.

PMID: 38884110 PMC: 11180218. DOI: 10.46989/001c.117961.

What do cancer-specific T cells 'see'?.

Shah S, Al-Omari A, Cook K, Paston S, Durrant L, Brentville V Discov Immunol. 2024; 2(1):kyac011.

PMID: 38567060 PMC: 10917189. DOI: 10.1093/discim/kyac011.

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.

Penter L, Liu Y, Wolff J, Yang L, Taing L, Jhaveri A Blood. 2023; 141(15):1817-1830.

PMID: 36706355 PMC: 10122106. DOI: 10.1182/blood.2022018246.

Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics.

Penter L, Gohil S, Wu C Front Immunol. 2022; 12:788891.

PMID: 35046946 PMC: 8761982. DOI: 10.3389/fimmu.2021.788891.

References

Arshad N, Cresswell P . Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I. J Biol Chem. 2018; 293(25):9555-9569. PMC: 6016473. DOI: 10.1074/jbc.RA118.002836. View

Johanns T, Miller C, Liu C, Perrin R, Bender D, Kobayashi D . Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. Oncoimmunology. 2019; 8(4):e1561106. PMC: 6422384. DOI: 10.1080/2162402X.2018.1561106. View

Hobo W, Maas F, Adisty N, de Witte T, Schaap N, van der Voort R . siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood. 2010; 116(22):4501-11. DOI: 10.1182/blood-2010-04-278739. View

Green M, Rodig S, Juszczynski P, Ouyang J, Sinha P, ODonnell E . Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012; 18(6):1611-8. PMC: 3321508. DOI: 10.1158/1078-0432.CCR-11-1942. View

Bengsch B, Ohtani T, Khan O, Setty M, Manne S, OBrien S . Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity. 2018; 48(5):1029-1045.e5. PMC: 6010198. DOI: 10.1016/j.immuni.2018.04.026. View

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

Nelde A, Walz J, Kowalewski D, Schuster H, Wolz O, Peper J . HLA class I-restricted L265P-derived peptides as specific targets for lymphoma immunotherapy. Oncoimmunology. 2017; 6(3):e1219825. PMC: 5384368. DOI: 10.1080/2162402X.2016.1219825. View

Anguille S, Van Tendeloo V, Berneman Z . Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012; 26(10):2186-96. DOI: 10.1038/leu.2012.145. View

Brusic A, Hainz U, Wadleigh M, Neuberg D, Su M, Canning C . Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012; 1(7):1095-1103. PMC: 3494623. DOI: 10.4161/onci.20954. View

10.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani P . Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36(14):1428-1439. PMC: 6075855. DOI: 10.1200/JCO.2017.76.0793. View

11.

Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4):433-8. PMC: 7446107. DOI: 10.1038/nm.4051. View

12.

Carreno B, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti A . Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348(6236):803-8. PMC: 4549796. DOI: 10.1126/science.aaa3828. View

13.

Pierce R, FIELD E, Mutis T, Golovina T, Von Kap-Herr C, Wilke M . The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J Immunol. 2001; 167(6):3223-30. DOI: 10.4049/jimmunol.167.6.3223. View

14.

Hu Z, Ott P, Wu C . Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2017; 18(3):168-182. PMC: 6508552. DOI: 10.1038/nri.2017.131. View

15.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

16.

Cobbold M, De La Pena H, Norris A, Polefrone J, Qian J, English A . MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med. 2013; 5(203):203ra125. PMC: 4071620. DOI: 10.1126/scitranslmed.3006061. View

17.

Pont M, Hobo W, Honders M, van Luxemburg-Heijs S, Kester M, van Oeveren-Rietdijk A . LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application. Haematologica. 2015; 100(10):e419-22. PMC: 4591780. DOI: 10.3324/haematol.2015.125021. View

18.

Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

19.

Weng J, Baio F, Moriarty K, Torikai H, Wang H, Liu Z . Targeting B-cell malignancies through human B-cell receptor specific CD4 T cells. Oncoimmunology. 2016; 5(11):e1232220. PMC: 5139634. DOI: 10.1080/2162402X.2016.1232220. View

20.

Schuster S, Neelapu S, Gause B, Janik J, Muggia F, Gockerman J . Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011; 29(20):2787-94. PMC: 3139394. DOI: 10.1200/JCO.2010.33.3005. View